Stay updated on Empagliflozin Effect on Tissue Sodium in Heart Failure Clinical Trial
Sign up to get notified when there's something new on the Empagliflozin Effect on Tissue Sodium in Heart Failure Clinical Trial page.

Latest updates to the Empagliflozin Effect on Tissue Sodium in Heart Failure Clinical Trial page
- ChecktodayChange DetectedRevision updated from v3.4.2 to v3.4.3.SummaryDifference0.1%

- Check7 days agoNo Change Detected
- Check15 days agoChange DetectedAdded the final published reference (Eur J Heart Fail, 2025) and removed the online-ahead-of-print citation for the study publications section.SummaryDifference0.1%

- Check29 days agoChange DetectedRevision: v3.4.2 was added. The long notice about government funding lapses and the previous Revision: v3.4.1 entry were removed.SummaryDifference0.5%

- Check37 days agoChange DetectedA site-wide notice about a lapse in government funding and the NIH Clinical Center's operating status was added, including links to cc.nih.gov and opm.gov. The page revision was updated from v3.4.0 to v3.4.1.SummaryDifference0.5%

- Check44 days agoChange DetectedAdded a glossary display option and a new QC-related label ('Last Update Submitted that Met QC Criteria'), updated FEAR Act labeling, and bumped the revision to v3.4.0. The previous QC label capitalization and version 3.3.4 were removed.SummaryDifference0.2%

- Check58 days agoChange DetectedRevision updated from v3.3.3 to v3.3.4 on the page. This is a minor site update and does not change study details or content.SummaryDifference0.1%

Stay in the know with updates to Empagliflozin Effect on Tissue Sodium in Heart Failure Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Empagliflozin Effect on Tissue Sodium in Heart Failure Clinical Trial page.